Predictors of Survival for Complete Clinical Responders to Definite Chemoradiation or Radiation Therapy for Esophageal Cancer
The aim of this study is to identify prognostic factors for outcome in patients being complete clinical responders with chemoradiation or radiation for esophageal cancer
NCT01525953 — Esophageal Cancer
Status: Completed
http://inclinicaltrials.com/esophageal-cancer/NCT01525953/
Biomarker Analysis of Gastrointestinal Cancer
BIOMARKER ANALYSES 1. FNA Sample: From each enrolled patient who meets the inclusion criteria, FNA sample will only be taken . FNA will be carried out only in patients with feasible biopsy or FNA site. Ascites or pleural fluid will be collected for analysis 2. Blood Samples From each enrolled patient who meets the inclusion criteria, blood samples will be collected. 3 mL blood sample will be collected . 3. tumor tissue Archived Tumor Tissue (Slides) Samples Primary tumor and/or a metastatic lesion collected. Approximately 5 unstained slides (if available) are collected.
NCT01484444 — Gastrointestinal Cancer
Status: Recruiting
http://inclinicaltrials.com/gastrointestinal-cancer/NCT01484444/
Distinction Between Lung Cancer and Gynecological Cancers by Exhalation Analysis and Canine Scent Detection
Previous studies have shown that specially trained sniffer dogs are capable to discriminate breath samples of patients with lung cancer and healthy individuals. So far it is not known whether this differentiation is specific for lung cancer or just identifies any form of (solid) tumor. Therefore, the dog's ability to differentiate between lung cancer, breast cancer and ovarian cancer is tested.
NCT01383408 — Breast Cancer
Status: Terminated
http://inclinicaltrials.com/breast-cancer/NCT01383408/
Analysis of Inherited Cancers
This study will analyze tumor tissue from patients with known genetic mutations (BRCA1, BRCA2, CHK2, etc) who have tumor tissue available from two surgeries, either primary/recurrent, or two different anatomical sites.
NCT01167842 — Breast Cancer
Status: Completed
http://inclinicaltrials.com/breast-cancer/NCT01167842/
Molecular Analysis of Liver Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at biomarkers in stored tumor samples from younger patients with liver cancer.
NCT00899002 — Liver Cancer
Status: Withdrawn
http://inclinicaltrials.com/liver-cancer/NCT00899002/
Serum Glycan Analysis in Breast Cancer
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur and identify biomarkers related to cancer. PURPOSE: This research study is looking at blood glycan biomarkers in women with stage IV breast cancer.
NCT00897962 — Breast Cancer
Status: Completed
http://inclinicaltrials.com/breast-cancer/NCT00897962/
Prediction of Therapeutic Response Using AQUA™ Quantitative Protein Expression Analysis of ER, PgR, and HER2 of Breast Cancer Tissue Microarrays From SWOG Protocol 9313
RATIONALE: Studying the proteins expressed in tumor tissue samples in the laboratory from patients with cancer may help doctors learn more about biomarkers related to cancer. It may also help doctors predict how patients respond to treatment. PURPOSE: This laboratory study is looking at protein expression in predicting response to treatment using tumor tissue samples from women with stage I, stage II, or stage IIIA breast cancer treated on clinical trial SWOG-9313.
NCT00896727 — Breast Cancer
Status: Completed
http://inclinicaltrials.com/breast-cancer/NCT00896727/
Molecular Analysis Of Bladder Cancer
This is a laboratory study where the investigators hope to look at chromosomal events implicated in bladder cancer.
NCT00871754 — Bladder Cancer
Status: Active, not recruiting
http://inclinicaltrials.com/bladder-cancer/NCT00871754/
Genetic Analysis of Liver Cancer
Liver cancer is a leading cause of cancer deaths worldwide. While the molecular pathogenesis of liver cancer has been extensively studied, less is known about how the molecular biology of liver cancer influences clinical outcome and treatment response. We are developing a translational research program that will characterize molecular changes in liver cancer. We plan to use molecular information obtained from studying liver tumor tissues to develop new diagnostics and treatment regimens for patients with these cancers. The experimental approach will require freezing fresh tumor tissues obtained from surgical procedures, which will be subsequently used for analysis of DNA, protein and mRNA expression. Many patients with liver cancer are referred to the Stanford Liver Tumor Board for consultation and treatment recommendations. We propose to gather tissue samples from those who subsequently undergo biopsy, liver resection surgery, or transplant surgery.
NCT00768001 — Hepatitis C
Status: Terminated
http://inclinicaltrials.com/hepatitis-c/NCT00768001/
Quality of Life Analysis of Prostate Cancer Patient's Therapy
This is an open label, non-interventional quality of life analysis for Zoladex treated prostate cancer patients by investigator's questionnaire
NCT00692874 — Prostate Cancer
Status: Completed
http://inclinicaltrials.com/prostate-cancer/NCT00692874/